Cargando…

Altered expression profile of BAFF receptors on peripheral blood B lymphocytes in Graves’ disease

BACKGROUND: B lymphocyte activating factor (BAFF) is a growth factor regulating B lymphocytes survival and maturation. Serum BAFF levels were elevated in patients affected with autoimmune thyroid diseases (AITD), including Graves’ disease (GD) and Hashimoto’s thyroiditis (HT). The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xin, Huang, Jinhui, Zhang, Aixia, Fang, Chen, Ma, Qi, Jiang, Pengjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082831/
https://www.ncbi.nlm.nih.gov/pubmed/33926416
http://dx.doi.org/10.1186/s12902-021-00752-3
_version_ 1783685912532615168
author Wang, Xin
Huang, Jinhui
Zhang, Aixia
Fang, Chen
Ma, Qi
Jiang, Pengjun
author_facet Wang, Xin
Huang, Jinhui
Zhang, Aixia
Fang, Chen
Ma, Qi
Jiang, Pengjun
author_sort Wang, Xin
collection PubMed
description BACKGROUND: B lymphocyte activating factor (BAFF) is a growth factor regulating B lymphocytes survival and maturation. Serum BAFF levels were elevated in patients affected with autoimmune thyroid diseases (AITD), including Graves’ disease (GD) and Hashimoto’s thyroiditis (HT). The aim of this study is to explore the association of expression levels of BAFF and its receptors with AITD. METHODS: Fifty-two GD patients, 39 Hashimoto’s thyroiditis (HT) patients and 23 healthy controls (HC) were recruited in this study. Serum BAFF levels were measured by ELISA. Expression of BAFF receptors, including BAFF receptor 3 (BR3) and transmembrane activator and calcium-modulating and cyclophilin ligand interactor (TACI), on B lymphocytes were analyzed by flowcytometry. Effects of steroids on serum BAFF levels and expression of BR3 and TACI were also observed in 10 patients with Graves’ orbitopathy (GO) receiving steroids therapy. RESULTS: Serum BAFF levels were significantly elevated from 0.93 ± 0.24 ng/ml in HC to 1.18 ± 0.33 ng/ml in GD (P = 0.0027) and 1.02 ± 0.24 ng/ml in HT (P = 0.0331). BR3 expression on peripheral B lymphocytes were elevated in GD (mean MFI: 4.52 ± 2.06 in GD vs. 3.00 ± 0.87 in HC, P = 0.0015), while TACI expression on peripheral B lymphocytes were decreased in GD without significance (mean MFI: 7.96 ± 4.06 in GD vs. 9.10 ± 3.37 in HC, P = 0.1285). Expression of BR3 and TACI was not changed significantly in HT patients. Steroids significantly suppressed serum BAFF concentrations (from 1.18 ± 0.27 ng/ml to 0.97 ± 0.10 ng/ml, P = 0.0364) and BR3 expression in GO patients (mean MFI from 6.26 ± 4.91 to 4.05 ± 1.58, P = 0.0083). CONCLUSIONS: Altered expression of BAFF and its receptor may mediate the autoimmunity in GD. Restoring the normal expression profile of receptors for BAFF could be a new strategy to treat GD.
format Online
Article
Text
id pubmed-8082831
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80828312021-04-29 Altered expression profile of BAFF receptors on peripheral blood B lymphocytes in Graves’ disease Wang, Xin Huang, Jinhui Zhang, Aixia Fang, Chen Ma, Qi Jiang, Pengjun BMC Endocr Disord Research Article BACKGROUND: B lymphocyte activating factor (BAFF) is a growth factor regulating B lymphocytes survival and maturation. Serum BAFF levels were elevated in patients affected with autoimmune thyroid diseases (AITD), including Graves’ disease (GD) and Hashimoto’s thyroiditis (HT). The aim of this study is to explore the association of expression levels of BAFF and its receptors with AITD. METHODS: Fifty-two GD patients, 39 Hashimoto’s thyroiditis (HT) patients and 23 healthy controls (HC) were recruited in this study. Serum BAFF levels were measured by ELISA. Expression of BAFF receptors, including BAFF receptor 3 (BR3) and transmembrane activator and calcium-modulating and cyclophilin ligand interactor (TACI), on B lymphocytes were analyzed by flowcytometry. Effects of steroids on serum BAFF levels and expression of BR3 and TACI were also observed in 10 patients with Graves’ orbitopathy (GO) receiving steroids therapy. RESULTS: Serum BAFF levels were significantly elevated from 0.93 ± 0.24 ng/ml in HC to 1.18 ± 0.33 ng/ml in GD (P = 0.0027) and 1.02 ± 0.24 ng/ml in HT (P = 0.0331). BR3 expression on peripheral B lymphocytes were elevated in GD (mean MFI: 4.52 ± 2.06 in GD vs. 3.00 ± 0.87 in HC, P = 0.0015), while TACI expression on peripheral B lymphocytes were decreased in GD without significance (mean MFI: 7.96 ± 4.06 in GD vs. 9.10 ± 3.37 in HC, P = 0.1285). Expression of BR3 and TACI was not changed significantly in HT patients. Steroids significantly suppressed serum BAFF concentrations (from 1.18 ± 0.27 ng/ml to 0.97 ± 0.10 ng/ml, P = 0.0364) and BR3 expression in GO patients (mean MFI from 6.26 ± 4.91 to 4.05 ± 1.58, P = 0.0083). CONCLUSIONS: Altered expression of BAFF and its receptor may mediate the autoimmunity in GD. Restoring the normal expression profile of receptors for BAFF could be a new strategy to treat GD. BioMed Central 2021-04-29 /pmc/articles/PMC8082831/ /pubmed/33926416 http://dx.doi.org/10.1186/s12902-021-00752-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Wang, Xin
Huang, Jinhui
Zhang, Aixia
Fang, Chen
Ma, Qi
Jiang, Pengjun
Altered expression profile of BAFF receptors on peripheral blood B lymphocytes in Graves’ disease
title Altered expression profile of BAFF receptors on peripheral blood B lymphocytes in Graves’ disease
title_full Altered expression profile of BAFF receptors on peripheral blood B lymphocytes in Graves’ disease
title_fullStr Altered expression profile of BAFF receptors on peripheral blood B lymphocytes in Graves’ disease
title_full_unstemmed Altered expression profile of BAFF receptors on peripheral blood B lymphocytes in Graves’ disease
title_short Altered expression profile of BAFF receptors on peripheral blood B lymphocytes in Graves’ disease
title_sort altered expression profile of baff receptors on peripheral blood b lymphocytes in graves’ disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082831/
https://www.ncbi.nlm.nih.gov/pubmed/33926416
http://dx.doi.org/10.1186/s12902-021-00752-3
work_keys_str_mv AT wangxin alteredexpressionprofileofbaffreceptorsonperipheralbloodblymphocytesingravesdisease
AT huangjinhui alteredexpressionprofileofbaffreceptorsonperipheralbloodblymphocytesingravesdisease
AT zhangaixia alteredexpressionprofileofbaffreceptorsonperipheralbloodblymphocytesingravesdisease
AT fangchen alteredexpressionprofileofbaffreceptorsonperipheralbloodblymphocytesingravesdisease
AT maqi alteredexpressionprofileofbaffreceptorsonperipheralbloodblymphocytesingravesdisease
AT jiangpengjun alteredexpressionprofileofbaffreceptorsonperipheralbloodblymphocytesingravesdisease